The treatment option for AIDS have drastically changed since 1987 when the first drug of HIV/AIDS Zidovudin (ZDV) was approved, mono therapy has been replaced by the most effective currently is HAART which includes three drugs from one or all the three categories to decrease incidence of viral resistance. + cell count recoveries of EFV and NRTIs were higher than NVP and NRTIs. ZDV/3TC/EFV mean CD4 count was greater than TDF/3TC/EFV.
INTRODUCTION
The treatment option for AIDS have drastically changed since 1987 when the first drug for HIV/AIDS Zidovudin (ZDV) was approved by the Food and Drug administration (FDA), even though there is still no cure for it. Mono therapy has been replaced by highly active antiretroviral therapy (HAART), which has reduced the incidence of viral resistance. As a high viral load is associated with HIV related morbidity and mortality, the goal of Antiretroviral therapy (ART) is to achieve Human immunodeficiency virus (HIV) viral suppression and reduce the level of HIV RNA to as low as level as possible, for as long as possible, restore and preserve immunological function, improve quality of life, reduce HIV related morbidity and mortality and reduce HIV transmission from mother to new born children 1, 2 . . According to recent WHO guideline recommended first line ARV regimens in adults and adolescents naïve patients consists: AZT/3TC/NVP or EFV and TDF/3TC or FTC/NVP or EFV, where as d4T or AZT/3TC/ATV/r or LPV/r, TDF/3TC or FTC/ATV/r or LPV/r and rarely ddI and ABC included regimens are second line treatments 6 . Effective ART should restore and preserve immunological function. The effectiveness of ART is assessed by clinical observation, determination of CD 4 . A prospective cohort study conducted in Cameroon on total of 169 patients was enrolled between January 2001 and April 2003; 85 of them received ZDV/3TC/NVP and 84 received d4T/3TC/NVP. Most of the patient characteristics were similar in the ZDV and d4T groups. However, compared to patients in the d4T group, those in the ZDV group had known their HIV sero status for a longer time (37.5 VS 20.2 months) and they also had a higher viral load (5 log 10 copies/ml, 67 % VS, 57 %). In contrast, the CD 4 cell count tended to be higher in ZDV group patients than in those receiving a d4T based regimen (152 Vs 117/mm 3 ), although the difference did not reach statistical significance 9 . A retrospective study conducted in Australia to assess and compare the efficacy and safety of three triple combination antiretroviral therapies in seventy HIV-1 infected treatment naïve adult patients with CD 4 + Tcell counts >50 cells/mm 3 were randomized to receive either ZDV/3TC/NVP, d4T/ Didanosine(ddI)/NVP or d4T/3TC/NVP for 52 weeks. The mean increases in CD 4 + Tcell counts in the AZT/3TC/NVP, d4T/3TC/NVP and d4T/ddI/NVP 
MATERIALS AND METHODS
The study was conducted in JUSH located in Jimma town, Oromia regional state about 348 km south west of the capital Addis Ababa. JUSH is one of the biggest health services delivering hospital in Oromia region. There were about 2707 PLWHA on ART follow up. JUSH was chosen for this studies mainly because of fact that, it is one of the main specialized and teaching hospitals of the country with separate clinic for PLWHA and portable to collect data. Thus good combination of sample groups even from the nearby rural areas with different living styles could be included in the study. A Cross-sectional retrospective study on data (from June 2006 to October 1, 2013 G.C) collected from patients records using data collection format was designed to assess the comparative effects of ART combination on CD 4 + count in JUSH from January 18 to 29, 2014 G. C. All PLWHA who were on HAART in JUSH were the source population for the study population was source of the study. All PLWHA individuals age greater than 15, non-pregnant and who treated with the same regimen at least for six month. Each participant must have had CD 4 + cell count records of baseline and at six month. Data was collected only from patient cards accessible during data collection. Potential participants were excluded if there were insufficient data to be included in the analysis.
Ethical Consideration
The data collection was started after getting full consent from administrative bodies of Jimma University Specialized Hospital (JUSH). The student research programme office of Jimma University offered a letter for the administrative bodies of the hospital.
RESULTS
A total of 2595 PLWHA were initiated on HAART from June 2006 to October 1, 2013 at JUSH. But during data collection only 1553 patients' cards were available in data room. Among these, 27 were dead, 61 were dropped, 7 were lost to follow up, 64 were switched treatment regimen, 51 were transferred out to other health fertilities and 80 were under fifteen children. A total of 1021 PLWHA on HAART had incomplete CD 4 cell count records of either baseline or at 6 th month. Only 123 PLWHA fulfilled the inclusion criteria and were included in study. Most patients (62 %) were on d4T/3TC/NVP and 3 % of the patients were on ZDV/3TC/EFV regimen ( Figure 1 ). The mean age at initiation of therapy was 31.89 (SD = 8.29) and the majority (62.6 %) of the participants were females. Mean baseline CD 4 + count of the study population was 146.84 cells/mm 3 (SD = 99.61) with females patients having higher CD 4 + count than male patients (Table 1 and Table 2 These findings are comparable with the multicenter international study conducted in 17 countries had found a median CD 4 cell count increased by +170 cells/mm 3 in NVP and +190 cells/mm 3 in EFV based regimen both with the d4T/3TC backbone at 48 weeks from baseline median just below 200 cells/mm 38 . The mean CD 4 + count change of d4T/3TC/NVP was lower than the mean CD 4 cell count of ZDV/3TC/NVP 257.27 cells/mm 3 (SD = 155.13) at 6 th month from baseline mean CD 4 count 129.93 cells/mm 3 (SD = 74.72). Similar to the result of this study, the comparative study conducted in Cameroon showed the median CD 4 + cell count in ZDV/3TC/NVP group patients were higher than in those receiving a d4T/3TC/NVP based regimen (152 V S 117cells/mm 3 ) 9 . Another comparative study conducted in Australia for 52 weeks also indicated the mean increases in . The comparative study of mean CD 4 cell count change of different types of ART treatment regimens of this study showed different outcomes of mean CD 4 + cell count increase at 6 th month of treatment initiation. The d4T/3TC/EFV regimen showed higher mean CD 4 + count change than ZDV/3TC/EFV regimen and compared to these EFV based regimens TDF/3TC/EFV showed lower mean CD 4 + cell count change. The NVP based combination ZDV/3TC/NVP have better mean CD 4 + cell count outcome than d4T/3TC/NVP regimen, but compared to EFV based regimens these have lower mean CD 4 + cell count outcome. The EFV and NVP based combinations both with d4T/3TC backbone were the most and the least effective on mean CD 4 + cell count increase respectively. Also the ZDV/3TC backbone EFV based regimen have more effective mean CD 4 + cell count change than NVP based regimen combined with the same d4T/3TC backbone. Other combination TDF/3TC backbone with EFV was superior to ZDV/3TC/NVP, but inferior to ZDV/3TC/EFV. The findings of this study that was observed at the 6 th month is also observed in a study conducted in Thailand where NRTIs backbone EFV based regimens resulted in better CD 4 cell count outcome than NVP based regimens with NRTIs backbone 12 .
